The Drug Regulatory Authority of Pakistan (DRAP) recently terminated the employment of Deputy Director Dr. Mohammad Aleem Akhtar, who had raised concerns about irregularities within the department. This incident, the second in less than three years, sheds light on the challenges faced by DRAP in addressing corruption issues.
Dr. Akhtar had sent 44 letters to various authorities, including the President, Prime Minister, and the National Accountability Bureau (NAB), alleging malpractice within DRAP. These claims, which lacked substantiation, caused embarrassment to DRAP and the pharmaceutical industry of Pakistan. Additionally, he was accused of unauthorized use of DRAP’s official letterheads.
Following a thorough evaluation, DRAP decided to terminate Dr. Akhtar’s employment under the Efficiency and Discipline (E and D) Rules of 2020. His allegations included accusations against the CEO of DRAP, suggesting a conflict of interest and violations of study leave rules. Read this Empty Hands, Full Hearts: The Resilience of Afghan Refugees Struggling to Rebuild Their Lives
This incident echoes a similar case in 2020, where a grade-18 officer, Dr. Obaid Ali, was dismissed for raising malpractice allegations. Despite claims of improper termination, the ministry asserted that due process was followed.
DRAP’s efforts to address corruption are evident, but challenges persist. Stay updated with the latest developments in DRAP and the pharmaceutical industry in Pakistan. Also Read Free Scholarships at University of Bradford: Study in UK for International Students, Pakistanis Included